High Levels of Epstein–Barr Virus DNA in Latently Infected Gastric Adenocarcinoma

DSpace/Manakin Repository

High Levels of Epstein–Barr Virus DNA in Latently Infected Gastric Adenocarcinoma

Citable link to this page


Title: High Levels of Epstein–Barr Virus DNA in Latently Infected Gastric Adenocarcinoma
Author: Ryan, Julie L; Morgan, Douglas R; Dominguez, Ricardo L; Thorne, Leigh B; Elmore, Sandra H; Mino-Kenudson, Mari; Lauwers, Gregory Y.; Booker, Jessica K; Gulley, Margaret L

Note: Order does not necessarily reflect citation order of authors.

Citation: Ryan, Julie L, Douglas R Morgan, Ricardo L Dominguez, Leigh B Thorne, Sandra H Elmore, Mari Mino-Kenudson, Gregory Y Lauwers, Jessica K Booker, and Margaret L Gulley. 2009. High levels of Epstein–Barr virus DNA in latently infected gastric adenocarcinoma. Laboratory Investigation 89(1): 80–90. doi:10.1038/labinvest.2008.103
Full Text & Related Files:
Abstract: Gastric adenocarcinoma is the second leading cause of cancer death worldwide. Epstein–Barr virus (EBV) is present in the malignant cells of approximately 10% of cases. It is unclear whether EBV is being missed in some gastric adenocarcinomas due to insensitive test methods or partial EBV genome loss. In this study, we screened 113 gastric adenocarcinomas from low- and high-incidence regions (United States and Central America) for the presence of EBV using a battery quantitative real-time PCR (Q-PCR) assays targeting disparate segments of the EBV genome (BamH1W, EBNA1, LMP1, LMP2, BZLF1, EBER1) and histochemical stains targeting EBV-encoded RNA (EBER), the latent proteins LMP1 and LMP2, and the lytic proteins BMRF1 and BZLF1. EBV DNA was detected by Q-PCR in 48/75 United States cancers (64%) and in 38/38 Central American cancers (100%), which was a significant differrence. EBER was localized to malignant epithelial cells in 8/48 (17%) United States and 3/38 (8%) Central American cancers. Viral loads were considerably higher for EBER-positive vs EBER-negative cancers (mean 162 986 vs 62 EBV DNA copies per 100 000 cells). A viral load of 2000 copies per 100 000 cells is recommended as the threshold distinguishing EBER-positive from EBER-negative tumors. One infected cancer selectively failed to amplify the LMP2 gene because of a point mutation, whereas another cancer had an atypical pattern of Q-PCR positivity suggesting deletion of large segments of the EBV genome. Three different viral latency profiles were observed in the cancers based on constant expression of EBER and focal or variable expression of LMP1 or LMP2, without lytic protein expression. We conclude that EBV DNA levels generally reflect EBER status, and a panel of at least two Q-PCR assays is recommended for sensitive identification of infected cancers.
Published Version: doi:10.1038/labinvest.2008.103
Other Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612099/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:32539299
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search